Levofloxacin

Generic Name: Levofloxacin

Brand Names: Levaquin, Quinsair

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀FN_₃O_₄

CAS Number: 100986-85-4

Unique Ingredient Identifier: RIX4E89Y14

Background: Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication: In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions: Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria

Associated Therapies: -

Clinical Trials

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Phase 3

Completed

Conditions: Tuberculosis, Multidrug-Resistant
Infection, Bacterial
Pulmonary Tuberculoses

Interventions: Drug: Control arm MDR-TB regimen, consistent with WHO guidelines
Drug: Bedaquiline
Drug: Clofazimine
Drug: Delamanid
Drug: Moxifloxacin
Drug: Linezolid
Drug: Levofloxacin
Drug: Pyrazinamide

First Posted Date: 2016-04-28

Last Posted Date: 2024-07-24

Lead Sponsor: Médecins Sans Frontières, France

Target Recruit Count: 754

Registration Number: NCT02754765

Locations: 🇵🇪
Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru
🇰🇿
National Center for Tuberculosis Problems, Almaty, Kazakhstan
🇬🇪
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

and more 9 locations

Levofloxacin in Bacterial Rhinosinussitis

Completed

Conditions: Rhinosinusitis

Interventions: Drug: Amoxicillin-Potassium Clavulanate Combination
Drug: Levofloxacin

First Posted Date: 2016-03-18

Last Posted Date: 2016-03-18

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 100

Registration Number: NCT02712502

Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus

Phase 3

Recruiting

Conditions: Infective Endocarditis

Interventions: Procedure: Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Drug: Levofloxacin
Drug: Rifampicin

First Posted Date: 2016-03-08

Last Posted Date: 2021-05-19

Lead Sponsor: University Hospital, Tours

Target Recruit Count: 324

Registration Number: NCT02701608

Locations: 🇫🇷
Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France
🇫🇷
Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France
🇫🇷
Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France

and more 51 locations

Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin

Phase 2

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Levofloxacin

First Posted Date: 2016-03-04

Last Posted Date: 2016-03-04

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 45

Registration Number: NCT02699658

Locations: 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand

Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori

Phase 4

Conditions: Helicobacter Pylori Gastrointestinal Tract Infection

Interventions: Drug: Clarithromycin
Drug: Levofloxacin

First Posted Date: 2016-02-26

Last Posted Date: 2017-03-21

Lead Sponsor: Damascus Hospital

Target Recruit Count: 74

Registration Number: NCT02693574

Locations: 🇸🇾
Damascus Hospital, Damascus, Syrian Arab Republic

A Two Week Nitazoxanidebased Quadruple Regimen

Phase 3

Conditions: Dyspepsia

Interventions: Drug: Nitazoxanide
Drug: Levofloxacin
Drug: Doxycyclin
Drug: Omeprazole

First Posted Date: 2015-12-03

Last Posted Date: 2018-01-03

Lead Sponsor: Tanta University

Target Recruit Count: 100

Registration Number: NCT02621359

Locations: 🇪🇬
Tropical medicine dept.-Tanta university hospital, Tanta, Egypt

Treatment Shortening of MDR-TB Using Existing and New Drugs

Phase 2

Conditions: Tuberculosis, Multidrug-Resistant

Interventions: Drug: Locally-used WHO-approved MDR-TB regimen in Korea
Drug: Linezolid
Drug: Delamanid
Drug: Levofloxacin
Drug: Pyrazinamide

First Posted Date: 2015-12-02

Last Posted Date: 2019-02-04

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 238

Registration Number: NCT02619994

Locations: 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of